Artwork

Content provided by Bobby Scott, Sandy Robertson, and Dawn Caviness. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bobby Scott, Sandy Robertson, and Dawn Caviness or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

#7 COPD Guidelines Update - Saving Lives One Eosinophil at a Time

31:15
 
Share
 

Manage episode 374831969 series 3428533
Content provided by Bobby Scott, Sandy Robertson, and Dawn Caviness. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bobby Scott, Sandy Robertson, and Dawn Caviness or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Are you checking eosinophil counts on your COPD patients? If not, it's time to start! Do you know which class of COPD medications have demonstrated a mortality benefit in RCTs? If not, you don't want to miss this one!
In the premiere episode of Season Two, Bobby and Sandy review updates from the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. We'll talk about some of the major changes, including the new and improved initial therapy diagram. We delve into key learnings from the IMPACT and ETHOS trials, and discuss why the LABA+ICS regimens recommended in previous guidelines are now discouraged.
Episode Outline:

  • Introduction - 01:35
  • The new and improved 2x2 therapy initiation table - 03:40
  • Recommended initial treatment - 05:58
  • Use of eosinophils to guide therapy - 09:12
  • Factors to consider when adding ICS - 16:33
  • Adjusting therapy in follow up - 18:20
  • Studies showing mortality benefit with triple therapy - 22:05
  • Potential downsides of triple therapy - 25:56
  • Wrap up/key takeaways - 28:23

Key Takeaways:

  • LABA+ICS is out, triple therapy is in! In patients with frequent COPD exacerbations, consider triple therapy (especially if they have eosinophils>300) but beware if history of repeated pneumonia, history of mycobacterial infection, or eos <100.
  • Triple therapy is the only pharmacological intervention for COPD with an associated mortality benefit
  • ABCD is gone, it’s now ABE. Be sure that you are doing a formal symptom assessment like the mMRC or CAT!
  • More patients are getting LAMA/LABA combination at start than previous guidelines. Now for all group B and E patients

Episode Links:

If you liked the episode, please leave a positive review and subscribe! Tell your colleagues and friends!
Comments/Questions/Suggestions? Email us at whatstheproofpodcast@gmail.com or find us on Twitter @theproofpodcast!
Credits:

  • Hosts: Bobby Scott, MD, FAAFP; Sandy Robertson, PharmD; Dawn Caviness, MD, BSN
  • Production & Cover Art: Bobby Scott, MD, FAAFP
  • Music: Twisterium, MondayHopes, Muzaproduction, and SergeQuadrado from Pixabay
  continue reading

10 episodes

Artwork
iconShare
 
Manage episode 374831969 series 3428533
Content provided by Bobby Scott, Sandy Robertson, and Dawn Caviness. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bobby Scott, Sandy Robertson, and Dawn Caviness or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Are you checking eosinophil counts on your COPD patients? If not, it's time to start! Do you know which class of COPD medications have demonstrated a mortality benefit in RCTs? If not, you don't want to miss this one!
In the premiere episode of Season Two, Bobby and Sandy review updates from the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. We'll talk about some of the major changes, including the new and improved initial therapy diagram. We delve into key learnings from the IMPACT and ETHOS trials, and discuss why the LABA+ICS regimens recommended in previous guidelines are now discouraged.
Episode Outline:

  • Introduction - 01:35
  • The new and improved 2x2 therapy initiation table - 03:40
  • Recommended initial treatment - 05:58
  • Use of eosinophils to guide therapy - 09:12
  • Factors to consider when adding ICS - 16:33
  • Adjusting therapy in follow up - 18:20
  • Studies showing mortality benefit with triple therapy - 22:05
  • Potential downsides of triple therapy - 25:56
  • Wrap up/key takeaways - 28:23

Key Takeaways:

  • LABA+ICS is out, triple therapy is in! In patients with frequent COPD exacerbations, consider triple therapy (especially if they have eosinophils>300) but beware if history of repeated pneumonia, history of mycobacterial infection, or eos <100.
  • Triple therapy is the only pharmacological intervention for COPD with an associated mortality benefit
  • ABCD is gone, it’s now ABE. Be sure that you are doing a formal symptom assessment like the mMRC or CAT!
  • More patients are getting LAMA/LABA combination at start than previous guidelines. Now for all group B and E patients

Episode Links:

If you liked the episode, please leave a positive review and subscribe! Tell your colleagues and friends!
Comments/Questions/Suggestions? Email us at whatstheproofpodcast@gmail.com or find us on Twitter @theproofpodcast!
Credits:

  • Hosts: Bobby Scott, MD, FAAFP; Sandy Robertson, PharmD; Dawn Caviness, MD, BSN
  • Production & Cover Art: Bobby Scott, MD, FAAFP
  • Music: Twisterium, MondayHopes, Muzaproduction, and SergeQuadrado from Pixabay
  continue reading

10 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide